Supplementary Table I. Demographic and clinical characteristics of additional 4 patients for validation step.

		MEFV Mutation	Signs and Symptoms	Treatment
Homozygote patients	Patient 7.DK	M694V/M694V	Fever, Peritonitis, Arthritis,	Anakinra
	Patient 8.NU	M694V/M694V	Fever, Peritonitis	Canakinumab
	Patient 9.GŞ	M694V/M694V	Fever, Peritonitis	Canakinumab
	Patient 10.HB	M694V/M694V	Fever, Peritonitis	Canakinumab
Heterozygote patients	Patient 7.FCG	M694V/-	Fever, Peritonitis	Colchicine
	Patient 8.COÖ	M694V/-	Fever, Peritonitis	Colchicine
	Patient 9.PMÖ	M694V/-	Fever, Peritonitis	Colchicine
	Patient 10.BFY	M694V/-	Fever, Peritonitis	Colchicine

Supplementary Table II. Complete Blood Count (CBC) levels of individuals in study group.

		Haemoglobin g/dL	Haematocrit %	Leukocyte x10^3/µL	Lymphocyte %	Monocyte %	Neutrophil %	Eosinophil %	Basophil %	Thrombocyte x10^3/µL
Homozygote patients	Patient 1. LZ	12.9	37.4	7.6	25.6	7.2	65	2	0.2	245
	Patient 2. DNU	11.3	34.1	10.8	13.5	4.2	82.1	0	0.2	230
	Patient 3. CI	16.1	46.9	7.9	31.1	9.8	56.4	2.1	0.6	287
	Patient 4. FK	13.9	43.6	11.5	24.2	11.7	61.5	2.2	0.4	326
	Patient 5. TB	11.4	34.4	5	34.1	9	54.3	1.9	0.7	255
	Patient 6. MK	12.5	38.7	13.2	18	7.2	74	0.4	0.4	500
Heterozygote patients	Patient 1. YEK	14.1	44.1	6.4	26.1	7.2	65.3	0.9	0.5	228
	Patient 2. RDZ	15.3	45.4	5	41.4	7.5	49.4	1.3	0.4	279
	Patient 3. BŞ	12.3	36.7	6.6	38.9	8.1	50.2	2.1	0.7	194
	Patient 4. EA	15.9	47.4	6.7	23.7	8.1	65.1	2.7	0.4	210
	Patient 5. MÇ	12.3	37.1	3.9	36.3	9.6	51.2	2.2	0.7	186
	Patient 6. YA	15.5	45.6	6.3	53.6	7.3	36.9	1.6	0.6	382
Heterozygote carriers	Carrier 1. NP	11.1	34	5.9	39.9	7.8	49.6	2	0.7	221
	Carrier 2. ZA	14.9	44	6.6	37.9	9.8	45.3	6.2	0.8	231
	Carrier 3. ST	14.9	43.8	11.1	23.2	6	69	1.3	0.5	284
	Carrier 4. SK	11.3	32.6	7.1	30.6	7.7	59.9	1.4	0.4	220
	Carrier 5. AB	14.3	41.7	8.8	27.8	10.3	57	4.3	0.6	313
	Carrier 6. IK	14.4	43	10.6	25.2	5.7	64.1	4.8	0.2	301
Healthy controls	Control 1. Aİ	15.5	46.2	5	23.3	10.7	64	1.3	0.7	318
	Control 2. DK	14.2	42.1	4.8	36	12	48.9	2.6	0.5	289
	Control 3. AY	12.6	37.5	7.8	29	5.8	63.4	1.5	0.3	306
	Control 4. MB	13.5	39.9	6.1	37.1	8.8	52.1	1.2	0.8	267
	Control 5. EAv	13.1	39.3	7.3	32.2	7.3	58.4	1.7	0.4	358
	Control 6 EY	15.9	48.7	7.1	32	8.8	57.6	1	0.6	280

Supplementary Table III. Complete Blood Count (CBC) levels of additional 4 patients for validation step.

		Haemoglobin g/dL	Haematocrit %	Leukocyte x10^3/µL	Lymphocyte %	Monocyte %	Neutrophil %	Eosinophil %	Basophil %	Thrombocyte x10^3/µL
Homozygote patients	Patient 7.DK	9.8	30.7	5.8	21.4	5.5	72.4	0.4	0.3	305
	Patient 8.NU	12.9	39	12.1	16.3	5.4	74.7	3.3	0.3	353
	Patient 9.GŞ	11.4	33.3	6.2	26.2	6.5	65.8	1	0.5	289
	Patient 10.HB	11.3	33.9	5.7	44.7	8.9	44.9	1.1	0.4	308
Heterozygote patients	Patient 7.FCG	14.4	42.6	6.9	37.3	6	55.4	0.6	0.7	326
	Patient 8.COÖ	15.1	42.5	7.8	42.5	7.7	47.8	1.5	0.5	215
	Patient 9.PMÖ	13.4	41.1	8.5	24.6	5.6	65.6	3.6	0.6	220
	Patient 10.BFY	13.7	40.7	6.7	49.9	4.7	43.1	1.9	0.4	365

Supplementary Table IV. CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) levels of 4 additional patients for validation step.

		CRP mg/dL	ESR mm/hour
Homozygote patients	Patient 7.DK	1.53	27
	Patient 8.NU	0.395	37
	Patient 9.GŞ	1.24	16
	Patient 10.HB	1.02	16
Heterozygote patients	Patient 7.FCG	0.219	2
	Patient 8.COÖ	0.401	2
	Patient 9.PMÖ	0.435	7
	Patient 10.BFY	0.794	8



Supplementary Fig. 1. KEGG Pathway analysis results on DAVID. Target genes for miR-20a are shown with red star in related pathways.



Supplementary Fig. 2. KEGG Pathway analysis results on DAVID. Target genes for miR-20a are shown with red star in related pathways.



Supplementary Fig. 3. KEGG Pathway analysis results on DAVID. Target genes for miR-574 are shown with red star in related pathways.



Supplementary Fig. 4. KEGG Pathway analysis results on DAVID. Target genes for miR-197 are shown with red star in related pathways.



Supplementary Fig. 5. KEGG Pathway analysis results on DAVID. Target genes for miR-197 are shown with red star in related pathways.



Supplementary Fig. 6. KEGG Pathway analysis results on DAVID. Target genes for miR- let-7d* are shown with red star in related pathways.



Supplementary Fig. 7. KEGG Pathway analysis results on DAVID. Target genes for miR- let-7d* are shown with red star in related pathways.